Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03336580
Recruitment Status : Terminated (Because of the impact of COVID-19 pandemic)
First Posted : November 8, 2017
Last Update Posted : August 20, 2020
Sponsor:
Information provided by (Responsible Party):
Prothena Biosciences Limited

Brief Summary:
A Phase 1, open-label study of intravenous (IV) PRX004 as a single agent in subjects with hereditary amyloid transthyretin (hATTR) amyloidosis. The study will consist of 3 phases and will enroll up to a total of 36 subjects. A 3+3 dose escalation component to determine the safety, tolerability, PK, PD, and MTD. An expansion component in anticipated PRX004 RP2D cohorts selected from the Dose Escalation Phase. An extended dosing component for eligible subjects from the Dose Escalation or Expansion phases.

Condition or disease Intervention/treatment Phase
Amyloidogenic Transthyretin (ATTR) Amyloidosis Drug: PRX004 Phase 1

Detailed Description:

This Phase 1, open-label consists of 3 phases. The Dose Escalation Phase is a 3+3 dose escalation component to determine the safety, tolerability, PK, PD, and MTD of IV PRX004 when given as a single agent in up to 36 evaluable subjects with hATTR amyloidosis. The Expansion Phase is an expansion component in anticipated PRX004 RP2D cohorts selected from the Dose Escalation Phase (this may occur in addition to cohorts in which additional subjects were added due to the observation of a dose-limiting [DLT] in the Escalation Phase). The Long-term Extension (LTE) Phase is an extended dosing component for eligible subjects from the Dose Escalation or Expansion phases.

The Dose Escalation Phase will follow a standard 3+3 design, in which cohorts of 3 to 6 subjects with hATTR amyloidosis will be enrolled at each dose level to receive IV PRX004 once every 28 days, based on scheduling from Month 1-Day 1 for up to 3 doses. Each subject will participate in only 1 dose escalation cohort. The starting dose of PRX004 will be 0.1 mg/kg.

Dose escalation will occur after the third evaluable subject in a cohort has completed the first 28 days following the first administration of PRX004. Up to 6 dose levels of PRX004 may be investigated (0.1, 0.3, 1, 3, 10, and 30 mg/kg) if tolerable. In the event the starting dose of 0.1 mg/kg is not tolerated, the dose escalationwill be halted and the study stopped.

Each subject will receive a maximum of 3 infusions of PRX004 in the Dose Escalation Phase. Subjects who complete the Month 3-Day 22 Visit in the Dose Escalation or Expansion phases may be eligible to receive up to 15 additional PRX004 infusions in the LTE Phase.

Each subject will receive a maximum of 3 infusions of PRX004 in the Dose Escalation Phase. Subjects who complete the Month 3-Day 22 Visit in the Dose Escalation or Expansion phases may be eligible to receive up to 15 additional PRX004 infusions in the LTE Phase.

Subjects who completed the EOS Visit in the Dose Escalation Phase prior to implementation of Protocol Amendment 2 may re-enter the study in the LTE Phase if they meet specific inclusion/exclusion criteria.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Dose Escalation Study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-label, Dose Escalation Study of Intravenous PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis
Actual Study Start Date : April 5, 2018
Actual Primary Completion Date : July 23, 2020
Actual Study Completion Date : July 23, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Amyloidosis

Arm Intervention/treatment
Experimental: PRX004

Dose escalation in up to 6 dose levels

Expansion of previously studied cohort(s) from Dose Escalation

Extended dosing at RP2D

Drug: PRX004

PRX004 (0.1, 0.3, 1, 3, 10, and 30 mg/kg) IV every 28 days

PRX004 IV every 28 days at RP2D(s)

PRX004 IV every 28 days at RP2D(s)





Primary Outcome Measures :
  1. Maximum Tolerated Dose of PRX004 [ Time Frame: 28 days ]
    Maximum Tolerated Dose of PRX004

  2. Number of subjects with treatment-emergent adverse events and clinically significant changes in ECGs, echocardiograms, cardiac telemetry, vital signs, and laboratory evaluations [ Time Frame: 3 months ]
    Number of subjects with treatment-emergent adverse events and clinically significant changes in ECGs, echocardiograms, cardiac telemetry, vital signs, and laboratory evaluations


Secondary Outcome Measures :
  1. PRX004 pharmacokinetic parameters - Cmin [ Time Frame: 3 months ]
    Minimum observed concentration (Cmin) of PRX004 in plasma

  2. PRX004 pharmacokinetic parameters -Cmax [ Time Frame: 3 months ]
    Maximum observed concentration (Cmax) of PRX004 in plasma

  3. PRX004 pharmacokinetic parameters - T1/2 [ Time Frame: 3 months ]
    Terminal elimination half-life (T1/2) of PRX004 in plasma

  4. PRX004 pharmacokinetic parameters -AUClast [ Time Frame: 3 months ]
    Area under the concentration-time curve from time zero to the last quantifiable concentration time-point (AUClast) of PRX004 in plasma

  5. PRX004 pharmacokinetic parameters -AUCtau [ Time Frame: 3 months ]
    Area under the concentration-time curve over the dosing interval (AUCtau) of PRX004 in plasma

  6. Immunogenicity indicators [ Time Frame: 3 months ]
    Immunogenicity indicators: Anti-drug antibodies (ADAs)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥18 years
  2. Ability to understand and willingness to sign an informed consent form prior to initiation of any study procedures
  3. Diagnosis of amyloidosis determined by polarizing light microscopy of green birefringent material in Congo Red-stained tissue specimens; and confirmed diagnosis of ATTR amyloidosis by immunohistochemistry, mass spectrometry, documentation of an ATTR mutation by gene sequencing, or 99m technetium-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) scans and/or technetium pyrophosphate (PYP) SPECT cardiac imaging. If scintigraphy is used for diagnosis then the grade must be 2 or greater, indicative of transthyretin amyloidosis-cardiomyopathy (ATTR-CM) (Gillmore, 2016)
  4. Known TTR mutation
  5. [Inclusion Criterion 5 removed in Amendment 2]
  6. Patients receiving concomitant tafamidis or diflunisal may enroll in the study, providing the dose has been stable for the last 6 months
  7. Karnofsky Performance Status (KPS) ≥60%
  8. Adequate organ function, including all of the following:

    1. Adequate bone marrow reserve, defined as the following: absolute neutrophil count ≥1.0 × 109/L; platelet count ≥100 × 109/L; hemoglobin ≥10 g/dL
    2. Hepatic: total bilirubin ≤ 2 times the upper limit of normal (× ULN), transaminases (aspartate aminotransferase and/or alanine aminotransferase) ≤3 × ULN; alkaline phosphatase ≤5 × ULN
    3. Renal: estimated glomerular filtration rate (eGFR) ≥45 mL/min/1.73 m2
  9. If currently receiving a diuretic, must have been on a stable dose for at least 4 weeks prior to the first dose of study drug
  10. Systolic blood pressure ≥90 mmHg and ≤180 mmHg
  11. Subjects with cardiomyopathy must have an NT-proBNP ≥650 pg/mL and ≤5000 pg/mL (ie, ≥76.9 pmol/L and ≤591 pmol/L) or evidence of septal wall thickening >1.2 cm on echocardiogram
  12. Must have a biopsy unless data are available from a previous one. The biopsy may be taken from any tissue or organ affected by ATTR amyloidosis (eg, skin, lip, abdominal fat pad, salivary gland), at the Investigator's discretion. Nerve biopsies are not required.
  13. Women of childbearing potential must have 2 negative pregnancy tests during Screening, the second within 24 hours prior to the first administration of study drug, and must agree to use highly effective physician-approved contraception from Screening to 90 days following the last study drug administration
  14. Male subjects must be surgically sterile or must agree to use highly effective physician-approved contraception from Screening to 90 days following the last study drug administration
  15. Polyneuropathy Disability (PND) Score ≤IIIB
  16. Neuropathy Impairment Score (NIS) ≥5 and ≤130

Exclusion Criteria:

  1. Amyloid light chain or other non-ATTR amyloidosis
  2. Any past history of or present abuse of alcohol, diabetes, B12 or folate deficiencies, autoimmune diseases, hereditary disorders other than transthyretin (eg, Charcot-Marie-Tooth), uncontrolled hypothyroidism, or other etiologies for the peripheral neuropathy
  3. Received prior liver transplant
  4. Planned liver transplant during the study
  5. Modified body mass index (mBMI) ≤600 kg/m2 × g/L
  6. New York Heart Association (NYHA) Functional Class III-IV (Appendix 2)
  7. LVEF ≤45%
  8. Uncontrolled symptomatic orthostatic hypotension
  9. Myocardial infarction, unstable or uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia, within 6 months prior to the first dose of study drug
  10. Any history of clinically significant sinus pauses on ECG
  11. Sinus pauses >3 seconds in the day or sinus pauses >5 seconds at night during the 48-hour pre-dose cardiac monitoring (ie, prior to first dose of study drug)
  12. Arrhythmia requiring treatment diagnosed during the 48-hour pre-dose cardiac monitoring (ie, prior to first dose of study drug). Note: subject could be reconsidered for entry into the study if appropriate treatment is obtained
  13. Hospitalized for heart failure within the 12 weeks prior to the first dose of study drug
  14. Uncontrolled infection, or active malignancy with the exception of the following:

    • Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer
    • Low risk prostate cancer with Gleason score <7 and prostate specific antigen <10 mg/mL
    • Any other cancer from which the subject has been disease-free for ≥2 years
  15. Clinically significant pleural effusion per Investigator (e.g., presence of pleural effusion ≥30% in either hemithorax)
  16. History of Grade ≥3 hypersensitivity-associated AEs or hypersensitivities to other monoclonal antibodies or the excipients found in the PRX004 formulation
  17. Known HIV infection or known hepatitis B or C virus carrier
  18. Women who are pregnant or breastfeeding
  19. Treatment with an investigational agent within 30 days or 5 half-lives (whichever is longer) prior to Month 1-Day 1
  20. Any condition which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the Medical Monitor or Investigator unacceptably increase the subject's risk by participating in the study
  21. Treatment with patisiran or inotersen within 90 days or 5 halflives (whichever is longer) prior to Month 1-Day 1

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03336580


Locations
Layout table for location information
United States, Massachusetts
Tufts Medical Center
Boston, Massachusetts, United States, 02111
United States, Minnesota
Mayo Clinic Minnesota
Rochester, Minnesota, United States, 55905
United States, Oregon
Oregon Health and Science University
Portland, Oregon, United States, 97239
United States, Pennsylvania
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania, United States, 19104
Portugal
Centro Hospitalar do Porto
Porto, Portugal
Spain
Hospital Universitario Puerta de Hierro - Majadahonda
Majadahonda, Madrid, Spain, 28222
Sweden
Umeå University Hospital
Umeå, Sweden
Sponsors and Collaborators
Prothena Biosciences Limited
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Prothena Biosciences Limited
ClinicalTrials.gov Identifier: NCT03336580    
Other Study ID Numbers: PRX004-101
2017-003521-15 ( EudraCT Number )
First Posted: November 8, 2017    Key Record Dates
Last Update Posted: August 20, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Amyloidosis
Proteostasis Deficiencies
Metabolic Diseases